Gilead seeks to defend HIV, reset I&I and bolster oncology

As Gilead works to expand its HIV franchise, the big biotech’s 2026 pipeline strategy also includes rebuilding in inflammation and immunology and strengthening oncology through business development.

In a conversation with BioCentury, Dietmar Berger, CMO of Gilead Sciences Inc. (NASDAQ:GILD), outlined the strategy for each of those three pillars. Taken together, the plan suggests Gilead is prioritizing reinforcement of existing franchises over any wholesale strategic reinvention...